Citadel Advisors’s MaxCyte MXCT Stock Holding History

Citadel Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122K	Buy	+99,400	New	+$99.1K	﹤0.01%	12516
2025 Q1	–	Sell	-6,000	Closed	-$25K	–	15210
2024 Q4	$25K	Buy	6,000 +4,000	+200%	+$15.1K	﹤0.01%	13032
2024 Q3	$7.78K	Sell	2,000 -700	-26%	-$2.95K	﹤0.01%	13342
2024 Q2	$10.6K	Buy	2,700 +600	+29%	+$2.58K	﹤0.01%	13078
2024 Q1	$8.8K	Sell	2,100 -600	-22%	-$2.82K	﹤0.01%	13532
2023 Q4	$12.7K	Sell	2,700 -6,600	-71%	-$25.7K	﹤0.01%	12977
2023 Q3	$29K	Buy	9,300 +5,300	+133%	+$21.3K	﹤0.01%	12297
2023 Q2	$18.4K	Buy	4,000 +1,400	+54%	+$6.43K	﹤0.01%	12802
2023 Q1	$12.9K	Buy	2,600 +1,900	+271%	+$9.36K	﹤0.01%	13383
2022 Q4	$3.82K	Buy	+700	New	+$4.29K	﹤0.01%	14168

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Citadel Advisors's MXCT Position: Q2 2026 in Review

Citadel Advisors increased its MaxCyte (MXCT) stake by 157% in Q2 2026, buying an estimated $521K and bringing the position to 856,318 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #8074.

Citadel Advisors first reported a position in MXCT in Q4 2021 and has held it in 19 quarters since. The position peaked at $11.6M in Q4 2022. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Citadel Advisors held 856,318 shares of MaxCyte worth $1.05M as of Q2 2026.
Citadel Advisors bought 523,230 MaxCyte shares in Q2 2026, an estimated $521K.
MaxCyte made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8074 holding.
Citadel Advisors first reported a position in MaxCyte in Q4 2021 and has held it in 19 quarters since.
Citadel Advisors's MaxCyte position peaked at $11.6M in Q4 2022.
123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.